Abstract Search

ea0099p2 | Adrenal and Cardiovascular Endocrinology | ECE2024

Prospective, multi-country, observational study of patients with endogenous Cushing’s syndrome exposed to Ketoconazole (using the existing European Registry on Cushing’s Syndrome (ERCUSYN)), to assess drug use, safety and effectiveness

Webb Susan , Santos Alicia , Aulinas Maso Anna , Tomsic Karin Zibar , Amaral Claudia , Feelders Richard , Ragnarsson Oskar , Ferrante Emanuele , Ceccato Filippo , Chabre Olivier , Cristante Justine , Hanzu Felicia , Reincke Martin , Chanson Philippe , Tabarin Antoine , Sequeira Duarte Joao , Guelho Daniela , Fajardo Carmen , Bostnavaron Martine , Bou Nader Myriam , Bertherat Jerome , Brue Thierry

Background: Ketoconazole is a steroidogenesis inhibitor approved in Europe for the treatment of endogenous Cushings syndrome (CS) based on retrospective studies published over 3 decades. We present interim data from the first prospective observational, multicenter, international study on ketoconazole, a non-interventional PASS (Post-Authorization Safety study) requested by EMA at the time of registration to confirm ketoconazole good tolerance and effectiveness. This stud...

0 shares

Endocrine Abstracts

Prospective, multi-country, observational study of patients with endogenous Cushing’s syndrome exposed to Ketoconazole (using the existing European Registry on Cushing’s Syndrome (ERCUSYN)), to assess drug use, safety and effectiveness

BiosciAbstracts